Hugel, Inc (145020) Fair Value & Analysis
Healthcare · KR · Market cap 2.6T KRW
Fair value as of: Jul 16, 2026
From 24 valuation models · updated 25 days ago
Share price +14.2% over the past month.
A strong business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (211,840 KRW to 405,711 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range 100,800 KRW – 388,000 KRW · fair‑value band 211,840 KRW – 405,711 KRW · the 273,500 KRW price screens below the 283,308 KRW fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Hugel, Inc (145020) currently trades at 273,500 KRW, while our model-based Fair Value estimate is 283,308 KRW, implying the stock looks roughly 3.6% fairly valued today. The Quality Score stands at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Hugel, Inc generated revenue of 452B KRW at a net margin of 33.4%. Revenue grew 29.9% year over year. It earns a return on equity of 16.4%. Net debt stands at 27.7B KRW. Fundamentals as of Jul 16, 2026
Our scenario range runs from 211,840 KRW (bear case) to 405,711 KRW (bull case); at 273,500 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 31% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 4%, 145020 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (378,089 KRW) versus Asset-Based (58,933 KRW). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 77 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles …
Full company description
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hugel, Inc reported revenue of 425B KRW in FY2025 versus 245B KRW in FY2021, a compound +14.8%/yr. Reported net income was 141B KRW in FY2025, compounding +25.0%/yr from FY2021.
Watch 145020: get an alert when its fair value changes →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 35/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Hugel, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hugel, Inc (145020) overvalued or undervalued?
What is the fair value of 145020?
What is the quality score of 145020?
What is the revenue of Hugel, Inc (145020)?
What is the net profit margin of 145020?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hugel, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.